Fig. 2: Incidence of neutropenia and diarrhea, and G-CSF use. | npj Breast Cancer

Fig. 2: Incidence of neutropenia and diarrhea, and G-CSF use.

From: Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

Fig. 2

a Incidence of neutropenia and diarrhea by grade, b use of G-CSF in the safety population, and c use of G-CSF by cycle in the safety population. Percent of patients using G-CSF by treatment cycle is based on the total number of patients treated in cycle 1 (SG, n = 258; TPC, n = 224). G-CSF granulocyte colony-stimulating factor, SG sacituzumab govitecan, TPC treatment of physician’s choice.

Back to article page